Tag Archives: Diabetes

Tales from the Road: The American Diabetes Association

We have just wrapped up our first exhibition at the American Diabetes Association (ADA) meeting in Chicago – which was a great experience and showed us that there is more opportunity to expand the reach of EECP® Therapy than ever before!

The show lasted from June 21st through 25th and was well attended with approximately 14,000 attendees from across the United States and around the world. The Vasomedical booth had a steady flow of interested attendees, and we spent a great deal of time educating attendees about EECP Therapy and the benefits it can have for patients.

The people we spoke with were fascinated to learn that EECP Therapy can provide relief to patients with angina symptoms such as chest or atypical pain, shortness of breath and fatigue, among others. This event was so relevant to our business because many patients with diabetes also have ischemic heart disease and can experience angina symptoms despite being on maximal medication. To our delight, numerous attendees commented that when they return home they are planning to speak to their cardiologists and hospitals about the positive effects EECP Therapy can have on their patients.

The attendees were interested to learn more about the clinical evidence recently published by the researchers at the University of Florida in Gainesville demonstrating the positive effects of EECP Therapy on glucose tolerance and insulin resistance.

At the exhibition, we also saw a great deal of interest in our BIOX ECG Holters and ambulatory blood pressure monitors as well as our EZ® pulse oximeters.

We thought the ADA was a successful conference, as we were able to raise awareness for EECP Therapy in this new patient population. We are continuing to learn more about diabetic patients and the potential impact EECP Therapy can have on this patient group’s quality of life.  We hope by next year’s ADA we have even more insight to share!

Next stop: Amsterdam, Netherlands!

Uptick of Type 2 Diabetes in Adolescents and Youth – How can we help?

Type 2 diabetes (T2D) has always been referred to as “adult-onset,” and generally considered not to affect adolescents and youth. However, the recent child obesity epidemic has led to an increased incidence of T2D in children and adolescents from 10-19 years of age, as reported in papers and editorial commentaries in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study in the June issue of Diabetes Care.

The most surprising and alarming results of the TODAY study are the fast rate of disease progression of T2D in youth compared to progression in an adult, the high rate of co-morbidities and subsequent complications and the inadequate treatment options for this patient population.

The TODAY study is an ongoing study supported by the National Institute of Health, monitoring more than 500 youth with T2D since 2004. Participants were randomly assigned to one of three treatment groups: metformin alone, metformin plus rosiglitazone, or metformin plus intensive life-style changes. The study found that the rate of deterioration of beta cell function (cells in the body that produce insulin to help transfer glucose into cells) in youth with T2D was four times higher than adults and only the group in the metformin plus rosiglitazone achieved a significant improvement in the preservation of beta function and insulin sensitivity.

Additionally, high blood pressure, kidney disease, body mass composition, eye disease, and cardiovascular risk factors, including lipid and inflammatory markers increased in proportion to the rise in A1C (a protein indicating the severity of T2D) and over time. The development of T2D among youth has significant public health consequences, as the complications of diabetes in kidney, eye and cardiovascular disease will be manifested during the most active and productive periods of their lives.

So what can we do to help address this issue?

For starters, Enhanced External Counterpulsation (EECP®) Therapy can potentially help this cohort of patients by managing the glycemic control in young people. There are published studies in medical journals with data demonstrating that EECP can improve the delivery of glucose to muscle cells where it will be utilized effectively and reduce insulin resistance by activating the glucose transporter which helps insulin transport glucose into cells. Furthermore, there is sufficient evidence showing that EECP can improve endothelial function, producing factors that neutralize oxidative stress and inflammatory markers, while also reducing the co-morbid complications. These complications occur at higher rates in T2D youth because they will have a longer time to endure diabetic complications.

Currently, it is a working hypothesis that EECP Therapy may reduce the deleterious impact diabetes has in the young population and our health care system; additional clinical studies have to be done to confirm this hypothesis. Although EECP is not currently cleared by the FDA for the treatment of T2D, the potential is clear, and at Vasomedical, we are devoting more effort and resources toward researching the benefits of this treatment for this particular patient population.